Evaluation of the risk of malignancy index in daily clinical management of adnexal masses

Abstract Objective To verify the effectiveness of the Risk of Malignancy Index in the discrimination between non-invasive (benign and borderline) lesions and invasive malignant adnexal masses in daily clinical practice. Methods This prospective observational study was conducted in a multicentre coop...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Gynecologic oncology 2010-03, Vol.116 (3), p.384-388
Hauptverfasser: van den Akker, Petronella A.J, Aalders, Anette L, Snijders, Marc P.L.M, Kluivers, Kirsten B, Samlal, Rahul A.K, Vollebergh, Jos H.A, Massuger, Leon F.A.G
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 388
container_issue 3
container_start_page 384
container_title Gynecologic oncology
container_volume 116
creator van den Akker, Petronella A.J
Aalders, Anette L
Snijders, Marc P.L.M
Kluivers, Kirsten B
Samlal, Rahul A.K
Vollebergh, Jos H.A
Massuger, Leon F.A.G
description Abstract Objective To verify the effectiveness of the Risk of Malignancy Index in the discrimination between non-invasive (benign and borderline) lesions and invasive malignant adnexal masses in daily clinical practice. Methods This prospective observational study was conducted in a multicentre cooperation of 11 hospitals. A total of 548 women with adnexal masses were included. Ultrasound characteristics, menopausal status and serum CA 125 level were registered preoperatively, and combined into the RMI afterwards. Final diagnosis was based on routine histopathologic examination. The decision to have patients operated by or with a gynecologic oncologist was based on the clinical impression of the gynecologist in the local hospital, based on physical examination, testing of serum samples, and ultrasound examination. This was compared with the hypothetical situation in which the RMI would have been applied as method of selection. Results An RMI of 200 achieved a sensitivity of 81% and specificity of 85% in the detection of ovarian cancer. Positive and negative predictive values were 48% and 96% respectively. In current practice, 64% of ovarian cancer patients were operated by a gynecologic oncologist. This percentage would have increased to 80% if the RMI with a cutoff value of 200 would have been used as method of selection. Conclusions In our study population, introduction of the RMI would improve the management of adnexal masses, with a higher percentage of ovarian cancer patients that are operated by a gynecologic oncologist. At the same time, referral of patients with non-invasive (benign and borderline) lesions would be reduced.
doi_str_mv 10.1016/j.ygyno.2009.11.014
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733689745</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S009082580900955X</els_id><sourcerecordid>733689745</sourcerecordid><originalsourceid>FETCH-LOGICAL-c413t-9f648385b97768b4b838140b5ccd0d1e7ff7cd69d827d286ffc0e5f27132f8143</originalsourceid><addsrcrecordid>eNqFkc1u1DAUhS1ERYfCEyCh7Fgl-CdO7AVIqGoLUiUWbSVYWY59PXiaOMVOqubt68wMQmLDxtfX_s6xfC5C7wiuCCbNx121bJcwVhRjWRFSYVK_QBuCJS8bweVLtMkXuBSUi1P0OqUdxphhQl-hUyIll5TwDfp58aj7WU9-DMXoiukXFNGn-3U_6N5vgw5mKXyw8JTXwmrfL4XpffBG9xkJegsDhGkVaBvgaX-aEqQ36MTpPsHbYz1Dd5cXt-dfy-vvV9_Ov1yXpiZsKqVrasEE72TbNqKru9yQGnfcGIstgda51thGWkFbS0XjnMHAHW0Joy6T7Ax9OPg-xPH3DGlSg08G-l4HGOekWsYaIduaZ5IdSBPHlCI49RD9oOOiCFZrpGqn9pGqNVJFiMJ7__dH_7kbwP7VHDPMwKcDAPmXjx6iSsZDMGB9BDMpO_r_PPD5H_2ffO9hgbQb5xhygIqoRBVWN-tU16HmkmfNf7Bn-KWd_A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733689745</pqid></control><display><type>article</type><title>Evaluation of the risk of malignancy index in daily clinical management of adnexal masses</title><source>Elsevier ScienceDirect Journals Complete - AutoHoldings</source><source>MEDLINE</source><creator>van den Akker, Petronella A.J ; Aalders, Anette L ; Snijders, Marc P.L.M ; Kluivers, Kirsten B ; Samlal, Rahul A.K ; Vollebergh, Jos H.A ; Massuger, Leon F.A.G</creator><creatorcontrib>van den Akker, Petronella A.J ; Aalders, Anette L ; Snijders, Marc P.L.M ; Kluivers, Kirsten B ; Samlal, Rahul A.K ; Vollebergh, Jos H.A ; Massuger, Leon F.A.G</creatorcontrib><description>Abstract Objective To verify the effectiveness of the Risk of Malignancy Index in the discrimination between non-invasive (benign and borderline) lesions and invasive malignant adnexal masses in daily clinical practice. Methods This prospective observational study was conducted in a multicentre cooperation of 11 hospitals. A total of 548 women with adnexal masses were included. Ultrasound characteristics, menopausal status and serum CA 125 level were registered preoperatively, and combined into the RMI afterwards. Final diagnosis was based on routine histopathologic examination. The decision to have patients operated by or with a gynecologic oncologist was based on the clinical impression of the gynecologist in the local hospital, based on physical examination, testing of serum samples, and ultrasound examination. This was compared with the hypothetical situation in which the RMI would have been applied as method of selection. Results An RMI of 200 achieved a sensitivity of 81% and specificity of 85% in the detection of ovarian cancer. Positive and negative predictive values were 48% and 96% respectively. In current practice, 64% of ovarian cancer patients were operated by a gynecologic oncologist. This percentage would have increased to 80% if the RMI with a cutoff value of 200 would have been used as method of selection. Conclusions In our study population, introduction of the RMI would improve the management of adnexal masses, with a higher percentage of ovarian cancer patients that are operated by a gynecologic oncologist. At the same time, referral of patients with non-invasive (benign and borderline) lesions would be reduced.</description><identifier>ISSN: 0090-8258</identifier><identifier>EISSN: 1095-6859</identifier><identifier>DOI: 10.1016/j.ygyno.2009.11.014</identifier><identifier>PMID: 19959215</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adnexal Diseases - blood ; Adnexal Diseases - diagnosis ; Adnexal Diseases - diagnostic imaging ; Adnexal Diseases - pathology ; Adnexal masses ; Adolescent ; Adult ; Aged ; Aged, 80 and over ; CA-125 Antigen - blood ; Cystadenocarcinoma, Serous - blood ; Cystadenocarcinoma, Serous - diagnosis ; Cystadenocarcinoma, Serous - diagnostic imaging ; Cystadenocarcinoma, Serous - pathology ; Female ; Genital Neoplasms, Female - blood ; Genital Neoplasms, Female - diagnosis ; Genital Neoplasms, Female - diagnostic imaging ; Genital Neoplasms, Female - pathology ; Hematology, Oncology and Palliative Medicine ; Humans ; Menopause ; Middle Aged ; Observation ; Obstetrics and Gynecology ; Preoperative evaluation ; Risk Assessment - methods ; Risk of malignancy index ; Severity of Illness Index ; Ultrasonography ; Ultrasound ; Young Adult</subject><ispartof>Gynecologic oncology, 2010-03, Vol.116 (3), p.384-388</ispartof><rights>Elsevier B.V.</rights><rights>2009 Elsevier B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c413t-9f648385b97768b4b838140b5ccd0d1e7ff7cd69d827d286ffc0e5f27132f8143</citedby><cites>FETCH-LOGICAL-c413t-9f648385b97768b4b838140b5ccd0d1e7ff7cd69d827d286ffc0e5f27132f8143</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ygyno.2009.11.014$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,778,782,3539,27907,27908,45978</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19959215$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van den Akker, Petronella A.J</creatorcontrib><creatorcontrib>Aalders, Anette L</creatorcontrib><creatorcontrib>Snijders, Marc P.L.M</creatorcontrib><creatorcontrib>Kluivers, Kirsten B</creatorcontrib><creatorcontrib>Samlal, Rahul A.K</creatorcontrib><creatorcontrib>Vollebergh, Jos H.A</creatorcontrib><creatorcontrib>Massuger, Leon F.A.G</creatorcontrib><title>Evaluation of the risk of malignancy index in daily clinical management of adnexal masses</title><title>Gynecologic oncology</title><addtitle>Gynecol Oncol</addtitle><description>Abstract Objective To verify the effectiveness of the Risk of Malignancy Index in the discrimination between non-invasive (benign and borderline) lesions and invasive malignant adnexal masses in daily clinical practice. Methods This prospective observational study was conducted in a multicentre cooperation of 11 hospitals. A total of 548 women with adnexal masses were included. Ultrasound characteristics, menopausal status and serum CA 125 level were registered preoperatively, and combined into the RMI afterwards. Final diagnosis was based on routine histopathologic examination. The decision to have patients operated by or with a gynecologic oncologist was based on the clinical impression of the gynecologist in the local hospital, based on physical examination, testing of serum samples, and ultrasound examination. This was compared with the hypothetical situation in which the RMI would have been applied as method of selection. Results An RMI of 200 achieved a sensitivity of 81% and specificity of 85% in the detection of ovarian cancer. Positive and negative predictive values were 48% and 96% respectively. In current practice, 64% of ovarian cancer patients were operated by a gynecologic oncologist. This percentage would have increased to 80% if the RMI with a cutoff value of 200 would have been used as method of selection. Conclusions In our study population, introduction of the RMI would improve the management of adnexal masses, with a higher percentage of ovarian cancer patients that are operated by a gynecologic oncologist. At the same time, referral of patients with non-invasive (benign and borderline) lesions would be reduced.</description><subject>Adnexal Diseases - blood</subject><subject>Adnexal Diseases - diagnosis</subject><subject>Adnexal Diseases - diagnostic imaging</subject><subject>Adnexal Diseases - pathology</subject><subject>Adnexal masses</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>CA-125 Antigen - blood</subject><subject>Cystadenocarcinoma, Serous - blood</subject><subject>Cystadenocarcinoma, Serous - diagnosis</subject><subject>Cystadenocarcinoma, Serous - diagnostic imaging</subject><subject>Cystadenocarcinoma, Serous - pathology</subject><subject>Female</subject><subject>Genital Neoplasms, Female - blood</subject><subject>Genital Neoplasms, Female - diagnosis</subject><subject>Genital Neoplasms, Female - diagnostic imaging</subject><subject>Genital Neoplasms, Female - pathology</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Menopause</subject><subject>Middle Aged</subject><subject>Observation</subject><subject>Obstetrics and Gynecology</subject><subject>Preoperative evaluation</subject><subject>Risk Assessment - methods</subject><subject>Risk of malignancy index</subject><subject>Severity of Illness Index</subject><subject>Ultrasonography</subject><subject>Ultrasound</subject><subject>Young Adult</subject><issn>0090-8258</issn><issn>1095-6859</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc1u1DAUhS1ERYfCEyCh7Fgl-CdO7AVIqGoLUiUWbSVYWY59PXiaOMVOqubt68wMQmLDxtfX_s6xfC5C7wiuCCbNx121bJcwVhRjWRFSYVK_QBuCJS8bweVLtMkXuBSUi1P0OqUdxphhQl-hUyIll5TwDfp58aj7WU9-DMXoiukXFNGn-3U_6N5vgw5mKXyw8JTXwmrfL4XpffBG9xkJegsDhGkVaBvgaX-aEqQ36MTpPsHbYz1Dd5cXt-dfy-vvV9_Ov1yXpiZsKqVrasEE72TbNqKru9yQGnfcGIstgda51thGWkFbS0XjnMHAHW0Joy6T7Ax9OPg-xPH3DGlSg08G-l4HGOekWsYaIduaZ5IdSBPHlCI49RD9oOOiCFZrpGqn9pGqNVJFiMJ7__dH_7kbwP7VHDPMwKcDAPmXjx6iSsZDMGB9BDMpO_r_PPD5H_2ffO9hgbQb5xhygIqoRBVWN-tU16HmkmfNf7Bn-KWd_A</recordid><startdate>20100301</startdate><enddate>20100301</enddate><creator>van den Akker, Petronella A.J</creator><creator>Aalders, Anette L</creator><creator>Snijders, Marc P.L.M</creator><creator>Kluivers, Kirsten B</creator><creator>Samlal, Rahul A.K</creator><creator>Vollebergh, Jos H.A</creator><creator>Massuger, Leon F.A.G</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20100301</creationdate><title>Evaluation of the risk of malignancy index in daily clinical management of adnexal masses</title><author>van den Akker, Petronella A.J ; Aalders, Anette L ; Snijders, Marc P.L.M ; Kluivers, Kirsten B ; Samlal, Rahul A.K ; Vollebergh, Jos H.A ; Massuger, Leon F.A.G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c413t-9f648385b97768b4b838140b5ccd0d1e7ff7cd69d827d286ffc0e5f27132f8143</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adnexal Diseases - blood</topic><topic>Adnexal Diseases - diagnosis</topic><topic>Adnexal Diseases - diagnostic imaging</topic><topic>Adnexal Diseases - pathology</topic><topic>Adnexal masses</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>CA-125 Antigen - blood</topic><topic>Cystadenocarcinoma, Serous - blood</topic><topic>Cystadenocarcinoma, Serous - diagnosis</topic><topic>Cystadenocarcinoma, Serous - diagnostic imaging</topic><topic>Cystadenocarcinoma, Serous - pathology</topic><topic>Female</topic><topic>Genital Neoplasms, Female - blood</topic><topic>Genital Neoplasms, Female - diagnosis</topic><topic>Genital Neoplasms, Female - diagnostic imaging</topic><topic>Genital Neoplasms, Female - pathology</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Menopause</topic><topic>Middle Aged</topic><topic>Observation</topic><topic>Obstetrics and Gynecology</topic><topic>Preoperative evaluation</topic><topic>Risk Assessment - methods</topic><topic>Risk of malignancy index</topic><topic>Severity of Illness Index</topic><topic>Ultrasonography</topic><topic>Ultrasound</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van den Akker, Petronella A.J</creatorcontrib><creatorcontrib>Aalders, Anette L</creatorcontrib><creatorcontrib>Snijders, Marc P.L.M</creatorcontrib><creatorcontrib>Kluivers, Kirsten B</creatorcontrib><creatorcontrib>Samlal, Rahul A.K</creatorcontrib><creatorcontrib>Vollebergh, Jos H.A</creatorcontrib><creatorcontrib>Massuger, Leon F.A.G</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Gynecologic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van den Akker, Petronella A.J</au><au>Aalders, Anette L</au><au>Snijders, Marc P.L.M</au><au>Kluivers, Kirsten B</au><au>Samlal, Rahul A.K</au><au>Vollebergh, Jos H.A</au><au>Massuger, Leon F.A.G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of the risk of malignancy index in daily clinical management of adnexal masses</atitle><jtitle>Gynecologic oncology</jtitle><addtitle>Gynecol Oncol</addtitle><date>2010-03-01</date><risdate>2010</risdate><volume>116</volume><issue>3</issue><spage>384</spage><epage>388</epage><pages>384-388</pages><issn>0090-8258</issn><eissn>1095-6859</eissn><abstract>Abstract Objective To verify the effectiveness of the Risk of Malignancy Index in the discrimination between non-invasive (benign and borderline) lesions and invasive malignant adnexal masses in daily clinical practice. Methods This prospective observational study was conducted in a multicentre cooperation of 11 hospitals. A total of 548 women with adnexal masses were included. Ultrasound characteristics, menopausal status and serum CA 125 level were registered preoperatively, and combined into the RMI afterwards. Final diagnosis was based on routine histopathologic examination. The decision to have patients operated by or with a gynecologic oncologist was based on the clinical impression of the gynecologist in the local hospital, based on physical examination, testing of serum samples, and ultrasound examination. This was compared with the hypothetical situation in which the RMI would have been applied as method of selection. Results An RMI of 200 achieved a sensitivity of 81% and specificity of 85% in the detection of ovarian cancer. Positive and negative predictive values were 48% and 96% respectively. In current practice, 64% of ovarian cancer patients were operated by a gynecologic oncologist. This percentage would have increased to 80% if the RMI with a cutoff value of 200 would have been used as method of selection. Conclusions In our study population, introduction of the RMI would improve the management of adnexal masses, with a higher percentage of ovarian cancer patients that are operated by a gynecologic oncologist. At the same time, referral of patients with non-invasive (benign and borderline) lesions would be reduced.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>19959215</pmid><doi>10.1016/j.ygyno.2009.11.014</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0090-8258
ispartof Gynecologic oncology, 2010-03, Vol.116 (3), p.384-388
issn 0090-8258
1095-6859
language eng
recordid cdi_proquest_miscellaneous_733689745
source Elsevier ScienceDirect Journals Complete - AutoHoldings; MEDLINE
subjects Adnexal Diseases - blood
Adnexal Diseases - diagnosis
Adnexal Diseases - diagnostic imaging
Adnexal Diseases - pathology
Adnexal masses
Adolescent
Adult
Aged
Aged, 80 and over
CA-125 Antigen - blood
Cystadenocarcinoma, Serous - blood
Cystadenocarcinoma, Serous - diagnosis
Cystadenocarcinoma, Serous - diagnostic imaging
Cystadenocarcinoma, Serous - pathology
Female
Genital Neoplasms, Female - blood
Genital Neoplasms, Female - diagnosis
Genital Neoplasms, Female - diagnostic imaging
Genital Neoplasms, Female - pathology
Hematology, Oncology and Palliative Medicine
Humans
Menopause
Middle Aged
Observation
Obstetrics and Gynecology
Preoperative evaluation
Risk Assessment - methods
Risk of malignancy index
Severity of Illness Index
Ultrasonography
Ultrasound
Young Adult
title Evaluation of the risk of malignancy index in daily clinical management of adnexal masses
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T07%3A16%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20the%20risk%20of%20malignancy%20index%20in%20daily%20clinical%20management%20of%20adnexal%20masses&rft.jtitle=Gynecologic%20oncology&rft.au=van%20den%20Akker,%20Petronella%20A.J&rft.date=2010-03-01&rft.volume=116&rft.issue=3&rft.spage=384&rft.epage=388&rft.pages=384-388&rft.issn=0090-8258&rft.eissn=1095-6859&rft_id=info:doi/10.1016/j.ygyno.2009.11.014&rft_dat=%3Cproquest_cross%3E733689745%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733689745&rft_id=info:pmid/19959215&rft_els_id=1_s2_0_S009082580900955X&rfr_iscdi=true